Furthermore, a long-term clinical study indicated that treatment with neutralizing IL-1β-specific antibodies dose-dependently reduced lung cancer incidence and mortality in a large cohort of patients with atherosclerosis with a history of myocardial infarction [66]. The gene discussed is IL1B; the disease is lung carcinoma.